Vallance says U.K. drug pricing needs fixing, confident industry can come back to the table

The U.K. government has heard loud and clear the message from the pharma industry: If it wants to keep their investment and resources in the country, the NHS must increase its spending on medicines. 

In a fireside chat at last week’s BioCentury Grand Rounds — Europe,  Patrick Vallance, minister of state for science, research and innovation, outlined his view of how to get beyond the current stalemate and stop pharmas from carrying out their threats to disinvest in the U.K. The discussion was moderated by Kate Bingham, managing partner at SV Health Investors and former chair of the U.K.’s vaccine task force during the COVID-19 pandemic. The conference was held in Cambridge, U.K., Sept. 17-19...